Pharmacokinetic and In-Vitro Characteristics of Sustained Release Verapamil Products
- 1 January 1990
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 16 (7) , 1233-1248
- https://doi.org/10.3109/03639049009114939
Abstract
The in-vitro dissolution and in-vivo pharmacokinetics of two marketed sustained release formulations, Verelan (V) and Isoptin SR (ISR), were compared. The effect of food on V was also examined in a separate study with conventional Isoptin (I) as a reference. Both sustained release preparations had extended dissolution profiles with 50% release times (T50%) of 4 hours for ISR and 8 hours for V. The extended in-vitro profile of V versus ISR was confirmed in-vivo with a Tmax of 7.3 hours compared to 5.0 hours, a Cmax of 114.3 compared to 171.0 and a peak to trough ratio of 3.8 compared to 10.1 for V and ISR respectively. In a second pharmacokinetic study the rate and extent of absorption of verapamil from V was shown to be unaffected by food.Keywords
This publication has 6 references indexed in Scilit:
- An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable anginaEuropean Journal of Clinical Pharmacology, 1988
- Assessment of ‘once daily’ verapamil for the treatment of hypertension using ambulatory, intra-arterial blood pressure recordingEuropean Journal of Clinical Pharmacology, 1987
- Sustained release verapamil, a once daily preparation: Objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable anginaJournal of the American College of Cardiology, 1987
- Antiarrhythmic DrugsDrugs, 1978
- VerapamilDrugs, 1978
- Physiological disposition of verapamil in manCardiovascular Research, 1976